BHV 5000

Drug Profile

BHV 5000

Alternative Names: BHV-5000

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Biohaven Pharmaceutical Holding Company
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Rett syndrome

Most Recent Events

  • 16 Jun 2017 Preclinical trials in Neuropsychiatric disorders in USA (PO) (Biohaven pipeline, June 2017)
  • 16 Jun 2017 Preclinical trials in Rett syndrome in USA (PO) (Biohaven pipeline, June 2017)
  • 16 Jun 2017 Biohaven plans a phase I pharmacokinetic trial for Rett syndrome in USA (PO) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top